The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Agendia; Amgen; Aristo; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; ClinSol; Daiichi Sankyo; Eisai; Genomic Health; GlaxoSmithKline; Hexal; Lilly; Medstrom Medical; MSD; Mundipharma; NanoString Technologies; Novartis; Odonate Therapeutics; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; RIEMSER; Roche; Sandoz/Hexal; Seagen; Tesaro; Teva
Speakers' Bureau - Agendia; Amgen; Aristo; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; ClinSol; Daiichi Sankyo; Eisai; Genomic Health; GlaxoSmithKline; Hexal; Lilly; Medstrom Medical; MSD; Mundipharma; NanoString Technologies; Novartis; Odonate Therapeutics; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; RIEMSER; Roche; Sandoz/Hexal; Seagen; Tesaro; Teva
Travel, Accommodations, Expenses - Agendia; Amgen; Aristo; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; ClinSol; Daiichi Sankyo; Eisai; Genomic Health; GlaxoSmithKline; Hexal; Lilly; Medstrom Medical; MSD; Mundipharma; NanoString Technologies; Novartis; Odonate Therapeutics; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; RIEMSER; Roche; Sandoz/Hexal; Seagen; Tesaro; Teva
De-escalated chemotherapy versus endocrine therapy plus pertuzumab+ trastuzumab for HR+/HER2+ early breast cancer (BC): First efficacy results from the neoadjuvant WSG-TP-II study.
 
Oleg Gluz
Consulting or Advisory Role - Celgene; Exact Sciences; Lilly; MSD; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Roche
 
Ulrike Nitz
Honoraria - Agendia; Amgen; Celgene; Genomic Health; NanoString Technologies; Novartis; Pfizer; Roche/Genentech; Teva
Consulting or Advisory Role - Genomic Health; Roche
Research Funding - Agendia (Inst); Amgen (Inst); Celgene (Inst); Genomic Health (Inst); NanoString Technologies (Inst); Roche (Inst); Sanofi (Inst)
Expert Testimony - Genomic Health
Travel, Accommodations, Expenses - Genomic Health; Pfizer; Roche
 
Matthias Christgen
No Relationships to Disclose
 
Sherko Kuemmel
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Genomic Health; Lilly; MSD Oncology; Novartis; Pfizer; pfm medical; Puma Biotechnology; Roche/Genentech; SOMATEX; Sonoscape
Travel, Accommodations, Expenses - Daiichi Sankyo; Roche; Sonoscape
(OPTIONAL) Uncompensated Relationships - West German Study Group
 
Johannes Holtschmidt
Honoraria - Roche Pharma AG
Travel, Accommodations, Expenses - Roche Pharma AG
 
Jan Priel
Employment - Palleos
 
Andreas Hartkopf
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; Eisai; Genomic Health; Lilly; MSD; Novartis; Pfizer; Roche; Teva
Speakers' Bureau - AstraZeneca; Clovis Oncology; Lilly; Novartis; Pfizer; Roche; Teva
Research Funding - Genomic Health; Novartis
 
Jochem Potenberg
No Relationships to Disclose
 
Kerstin Luedtke-Heckenkamp
Consulting or Advisory Role - Celgene; Lilly; Novartis; Roche
Research Funding - Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Celgene; Novartis; Pfizer; Roche
 
Marianne Just
No Relationships to Disclose
 
Pia Wuelfing
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Speakers' Bureau - Lilly; Novartis; Pfizer; Roche
 
Raquel von Schumann
No Relationships to Disclose
 
Monika Graeser
No Relationships to Disclose
 
Rachel Wuerstlein
No Relationships to Disclose
 
Ronald E. Kates
Honoraria - Amgen (I); Celgene (I); Genomic Health (I); NanoString Technologies (I); Novartis (I); Pfizer (I); Roche (I)
Consulting or Advisory Role - Agendia (I); AstraZeneca (I); Celgene (I); Daiichi Sankyo (I); Lilly (I); Merck Sharp & Dohme (I); Novartis (I); Odonate Therapeutics (I); Pfizer (I); Roche/Genentech (I); Sandoz (I)
 
Hans Heinrich Kreipe
Consulting or Advisory Role - AstraZeneca; Genomic Health; Novartis; Roche Pharma AG
Travel, Accommodations, Expenses - AstraZeneca; Genomic Health; Novartis; Roche Pharma AG
 
Nadia Harbeck
Stock and Other Ownership Interests - West German Study Group
Honoraria - Amgen; AstraZeneca; Genomic Health; Novartis; Pfizer; Pierre Fabre; Roche; Zodiac Pharma
Consulting or Advisory Role - Agendia; AstraZeneca; Celgene; Daiichi Sankyo; Lilly; Merck Sharp & Dohme; Novartis; Odonate Therapeutics; Pfizer; Pierre Fabre; Roche/Genentech; Sandoz; Seagen; West German Study Group (I)
Research Funding - Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)